Home
overview

Analgesics are among the most commonly prescribed drugs in the world and yet finding novel targets and mechanisms that may elevate hard to treat pain is becoming more difficult. After nearly 20 years of successful Pain Therapeutics conferences, join us for the 18th Annual Pain Therapeutics conference in May to explore novel targets for pain therapeutics, new translational approaches and pipeline drug development from the leading pharma companies in pain management.

 

With more case studies, improved networking opportunities and presentations on exciting cutting edge research, the 18th Annual Pain Therapeutics conference will equip you with the latest knowledge to advance your research and trials.

Benefits of attending:

  • Discover the novel targets for pain management and hear how leading pharma companies are utilising them to elevate pain across a range of pain types.
  • Learn from exciting case studies of analgesic drug development and trials.
  • Explore the mechanisms by which that latest drugs cure pain.
  • Discuss the future of pain therapeutics and how big data and technology are shaping the industry..
  • Advance your research and trials with the latest advice from the regulatory bodies
     

The upcoming Pain Therapeutics conference moves away from well discussed topics such as opioid dependence and animal models and focuses on the most exciting current research, opinions, novel targets and mechanisms and advances in the field of analgesic medicine

Who Should attend:

Chief Executive Officer, Chief Scientific Officers, Chief Medical Officers, Managing Directors, CEO, Head of Department, Principal Research Scientists, Clinical lead, Clinical Operations in the following fields:

  • Pain and Migraine
  • Inflammation
  • Chronic Pain
  • Neuropathic Pain
  • Analgesic pre-clinical development
  • Anaesthesia and Pain Management
  • CNS clinical trials
  • Ion Channel Pharmacology
  • Pharmacology Intelligence
  • Translational science
  • Drug development
  • Exploratory development

 

Past Attendees include:

AiCure; Amgen; Analgesia Partnership; Apollo Therapeutics; AstraZeneca; Bayer; Bayer AG; biogen; Cara Therapeutics ; Centre for Human Drug Research; Centrexion Therapeutics Corp.; Chdr; Clermont Universit; Convergence Pharmaceuticals; Daiichi Sankyo Co. Ltd.; Daiichi Sankyo co.ltd; Eli Lilly and Company; ENSCCF Sigma Clermont; Eupraxia Pharmaceuticals Inc; Family Cottage Sydney; GlaxoSmithKline; Grunenthal; Grunenthal GmbH; Gsk; Innopain; Ipsen Innovation; J & JPRD; Kings College London; Lucideon; MD Biosciences; Merck & Co.; MRC Technology; Mundipharma International Limited; Mundipharma International Ltd; Mundipharma Research; Mundipharma Research GmbH & Co. KG; Mundipharma Research Ltd; Nektar Therapeutics; NeuroDigm; Novartis; Pharmaleads; Premier Research; Queens University Belfast; Queen's University Belfast; Transpharmation Ltd; University of Manchester; US Army Institute for Surgical Research; Zoetis;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Joseph Stauffer

Joseph Stauffer, Chief Medical Officer, Cara Therapeutics
View Bio

9:10 Finding targets and using animal models appropriately for pain therapeutics

  • Translatability of preclinical evidence is debated in the pain field, but are there exceptions that prove (or disprove) the rule?
  • Alternatively, can we take an opportunistic approach and focus on targets with clinical evidence provided by serendipity?
  • This presentation will address these questions considering various examples including KCNQ2/3, TRP family, NGF and CGRP.
     
  • Jenny Laird

    Jenny Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    View Bio

    Lisa Broad

    Lisa Broad, Senior Research Advisor , Eli Lilly and Company
    View Bio

    9:50 Drug discovery approaches in neuropathic pain and migraine – apples and oranges or lemons and limes?

    Gordon Munro

    Gordon Munro, Senior Scientist, Danish Headache Centre
    View Bio

  • Therapeutics target distinct facets of disease pathophysiology in neuropathic pain and migraine
  • Shared neurobiological mechanisms in neuropathic pain and migraine
  • Limitations to drug development –animal models and/or patient populations
  • Harmonizing knowledge gained from neuropathic pain research and development with migraine drug discovery
     
  • 10:30 Morning Coffee

    11:00 Translational oppertunities and challenges in chronic pain

    Alexander Oksche

    Alexander Oksche, Executive Director , Mundipharma Research GmbH & Co. KG
    View Bio

  • Where are we in our understanding of chronic pain and about appropriate cellular targets?
  • How to bridge the translational gap from preclinical models to patient selection?
  • Will personalised medicine provide us with new avenues for mechanism-based treatments
  • Risk signatures and biomarkers – what are the opportunities and challenges in chronic pain?
     
  • 11:40 Pain vs Nociception: How appropriate is the use of animal models in pain therapeutics

  • Role of animal models in the failure of pain therapeutic development
  • How reliable are the surrogate markers for pain in animal models
  • What are the alternatives to animal models
  • Why do Pre-clinical trials still use animal models
     
  • Gordon Munro

    Gordon Munro, Senior Scientist, Danish Headache Centre
    View Bio

    Jenny Laird

    Jenny Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    View Bio

    Alexander Oksche

    Alexander Oksche, Executive Director , Mundipharma Research GmbH & Co. KG
    View Bio

    12:20 Networking Lunch

    13:20 Session Reserved for Lotus Clinical Research

    14:00 CR845: A novel kappa opioid receptor agonist for acute post-operative pain, chronic pain of osteoarthritis and pruritus

    Joseph Stauffer

    Joseph Stauffer, Chief Medical Officer, Cara Therapeutics
    View Bio

  • Discussion of unique pharmacology of CR845
  • Analysis of respiratory safety and abuse liability when used for treatment of pain
  • Summary of up to date results from phase II osteoarthritis trials
  • Future hopes for CR845
     
  • 14:40 CNTX-6970 a novel CCR2 antagonist with a unique analgesic signature

    Randall Stevens

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
    View Bio

  • Mechanism of action
  • Unique analgesic signature in preclinical models
  • Using Big Data to identify clinical development targets
  • Findings from Phase 1 clinical studies and next steps
     
  • 15:20 Afternoon Tea

    15:50 VM202, a DNA-based Potential Disease-Modifying Treatment for Painful Diabetic Neuropathy

    William Schmidt

    William Schmidt, Vice President, Clinical Development , Viromed
    View Bio

  • VM202 is a naked plasmid DNA vector engineered to express two isoforms of human hepatocyte growth factor (HGF).
  • In an ongoing Phase 3 clinical study, VM202 (8 mg/leg) or Placebo is administered i.m. to the calf muscle of each leg in a defined multi-injection pattern on Days 0 and 14 and again on Days 90 and 104.
  • Phase I/II and separate Phase 2 results show robust reductions in foot pain (p<0.05 vs. baseline) and a trend in improved sensory function through 9-12 months after initial treatment in subjects receiving VM202.
  • Pain relieving effects were more pronounced in patients who are not taking Lyrica (pregabalin) and/or Neurontin (gabapentin).
  • VM202 demonstrated an excellent safety profile in Phase I/II and Phase 2 clinical studies.
  • 16:30 Zilretta: Development of an extended release intra-articular therapeutic for osteoarthritis

    Toni Williamson

    Toni Williamson, Senior Director Non-Clinical Research, Flexion Therapeutics
    View Bio

  • Zilretta microsphere technology – how does it work?
  • The challenges of developing an extended release product
  • Summary of pre-clinical data
  • Summary of clinical studies
  • Case study examples
     
  • 17:10 Trial conduct in chronic pain conditions; Pitfalls and challenges

    Yanina Flossbach

    Yanina Flossbach, Associate Medical Director Neuroscience , Novartis Pharmaceuticals

  • Patient reported outcomes in clinical trials in pain
  • Reducing placebo responses
  • Patient recruitment challenges 
  • Data handling and management
  • Other considerations
     
  • 17:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Randall Stevens

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
    View Bio

    Kerrie Brady

    Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    View Bio

    9:10 The TREK 1 agonists, a promising way to solve the opioid crisis?

    Jean Deregnaucourt

    Jean Deregnaucourt, Scientific Director, Innopain
    View Bio

  • An exemple of TREK 1 agonists: the substituted acrilyc acid derivatives
  • In vitro and in vivo pharmacological profile
  • Challenges and promises for the future
     
  • 9:50 Development of NMDA receptor modulators in central pain disorders

    Torsten Madsen

    Torsten Madsen, CMO, Aptinyx
    View Bio

  • The NMDA receptor is an attractive therapeutic target for neuropathic and chronic pain disorders
  • The preclinical development, data and pharmacology of NYX-2925 will be presented
  • The clinical development strategy for NYX-2925 will discussed
     
  • 10:30 Morning Coffee

    11:00 Selective TARP-dependent AMPA Receptor Antagonists as a Novel Therapy for Chronic Pain

    Eric Nisenbaum

    Eric Nisenbaum, Head of Neurophysiology, Eli Lilly & Co
    View Bio

  • The role of AMPA receptors in synaptic plasticity in pain pathways
  • Expression and functional consequences of Transmembrane AMPA receptor Regulatory Proteins (TARPs)
  • Identification of TARP-dependent AMPA receptor antagonists
  • Evidence for LY3130481 (CERC-611) as a novel analgesic
  • 11:40 Drugging the un-druggable: P2X4 mAbs as therapeutics for pain

    Iain Chessell

    Iain Chessell, VP & Head, IMED Neuroscience , AstraZeneca
    View Bio

  • Novel approaches to discovery of antibodies to P2X4
  • Functional and electrophysiological characterisation
  • Reaching the CNS – application of novel BBB technologies to access the spinal cord with antibody therapies
  • Efficacy in preclinical models and next steps
     
  • 12:20 Round table discussion session

  • Depression and chronic pain – Does constant pain cause depression or is depression a co-symptom of pain caused by intrinsic changes to neurons?

    Iain Chessell

  • Opioid drugs – Amid an opioid crisis, do abuse resistant drugs work and are we doing enough to reduce harm from opioids?

    Joseph Stauffer

  • What can the pain therapeutics industry expect with the ageing population?

    Randall Stevens

  • How should patient engagement be managed clinical trials for analgesic drugs to reduce the placebo effect and increase the success of clinical trials?

    Kerrie Brady

  • Why are novel analgesic targets so challenging to find and target effectively with drugs?

    Jenny Laird

  • Can stem cells ever replace animal models in preclinical studies? – Benefits and challenges.

    Theo Meert

  • Are the Guideline documents, and interactions from regulatory bodies, sufficient for the pain therapeutics industry?

    Invitation to host to : MHRA
     

  • Kerrie Brady

    Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    View Bio

    Randall Stevens

    Randall Stevens, Chief Medical Officer, Centrexion Therapeutics Corp.
    View Bio

    Joseph Stauffer

    Joseph Stauffer, Chief Medical Officer, Cara Therapeutics
    View Bio

    Iain Chessell

    Iain Chessell, VP & Head, IMED Neuroscience , AstraZeneca
    View Bio

    Theo Meert

    Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutical NV, J&J
    View Bio

    Jenny Laird

    Jenny Laird, Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    View Bio

    13:00 Networking Lunch

    14:00 Big Data for Big Decisions

    Kerrie Brady

    Kerrie Brady, Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    View Bio

  • How to best develop a portfolio of novel non-opioid products for pain?
  • Integration of human expertise and artificial intelligence
  • Using metadata to qualify big data output
  • Can Big Data increase technical success for novel pain drug development?
     
  • 14:40 Development update on Erenumab

    Daniel Mikol

    Daniel Mikol, Executive Medicl Director Global Development Neuroscience, Amgen
    View Bio

  • The calcitonin gene-related peptide  (CGRP) pathway is pathophysiologically relevant in migraine
  • Erenumab is an investigational monoclonal antibody targeting the canonical receptor for CGRP
  • In episodic migraine prevention studies, erenumab has demonstrated efficacy in reducing migraine frequency and use of acute headache medications
  • In chronic migraine, erenumab has demonstrated efficacy in reducing migraine frequency and use of acute medications in patients with or without acute medication overuse
     
  • 15:20 Afternoon Tea

    15:50 New approaches to developing pain products

    Theo Meert

    Theo Meert, Head of Global Government Grant Office, Janssen Pharmaceutical NV, J&J
    View Bio

  • Search for proof of concept testing
  • Search for alternative development plans
  • New marketing/entry strategies needed?
     
  • 16:30 Case Study: NKTR-181- a novel approach to an old-school target

    Stephen Doberstein

    Stephen Doberstein , Senior Vice President, Research and Development and Chief R&D Officer, Nektar Therapeutics

  • Abuse liability of drugs is strongly related to their CNS pharmacokinetics
  • NKTR-181 is a first-in-class opioid analgesic with strategic brain entry kinetics
  • Limiting the rate of entry of mu-opioid agonists reduces their likeability
  • NKTR-181’s inherent long circulating half-life reduces withdrawal symptoms
  • Pivotal efficacy, safety, and abuse liability studies are completed
     
  • 16:30 Chairman’s Closing Remarks and Close of Day Two

    17:10 An industry perspective from Grunenthal

    Mark Field

    Mark Field, SVP, Head Global Clinical Development , Grunenthal Gmb H

  • Approaching pain as a disease – not just a symptom
  • Mapping the landscape of pain
  • Using a target-to-disease approach to identify novel compounds for development
     
  • +

    FEATURED SPEAKERS

    Daniel Mikol

    Daniel Mikol

    Executive Medicl Director Global Development Neuroscience, Amgen
    Iain Chessell

    Iain Chessell

    VP & Head, IMED Neuroscience , AstraZeneca
    Joseph Stauffer

    Joseph Stauffer

    Chief Medical Officer, Cara Therapeutics
    Kerrie Brady

    Kerrie Brady

    Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    Randall Stevens

    Randall Stevens

    Chief Medical Officer, Centrexion Therapeutics Corp.
    William Schmidt

    William Schmidt

    Vice President, Clinical Development , Viromed

    Alexander Oksche

    Executive Director , Mundipharma Research GmbH & Co. KG
    Alexander Oksche

    Alexander Oksche is Executive Director of Academic Alliances at Mundipharma Research GmbH & Co. KG focusing on R&D collaborations to advance scientific insights of internal drug development programmes. Alexander joined Mundipharma Research in 2006 to lead the internal R&D Innovation Process and later Pharmacological & Translational Science resulting in several drug development activities for the treatment of chronic pain. Alexander’s research areas cover classical and novel signalling pathways of G protein-coupled receptors and translational aspects of acute and chronic pain. He authored / co-author more than 40 peer-reviewed publications and of several book chapters. Alexander graduated as MD from Heinrich-Heine-University in Duesseldorf in 1992 and gained his PhD degree in Pharmacology and Toxicology from Charité Berlin in 2003. Since 2007 Alexander is lecturer in Pharmacology and has been appointed as Professor for Pharmacology at the Medical Faculty of the University Giessen in 2014.

    Daniel Mikol

    Executive Medicl Director Global Development Neuroscience, Amgen
    Daniel Mikol

    Daniel Mikol obtained his MD and PhD at the University of Chicago under Kari Stefansson, now deCODE CEO. He completed a Neurology residency at the University of California, San Francisco and fellowship at the University of Michigan. He continued to work on staff at the University of Michigan, an active clinician and clinical researcher, with interests in neuroimmunology. He left the University of Michigan in 2008 as Associate Professor, and since he has worked in global clinical development for several biotech companies, most recently joining Amgen in 2015 to lead the global development of erenumab (human anti-CGRP receptor mAb) for migraine prevention.

    Eric Nisenbaum

    Head of Neurophysiology, Eli Lilly & Co
    Eric Nisenbaum

    Dr. Nisenbaum received his B.S. in Psychology from Indiana University and his Ph.D. in Neuroscience from the University of Pittsburgh where his research focused on the relationship between changes in neurophysiological, neurochemical and behavioral indices in an animal model of Parkinson’s Disease. He subsequently went to the Department of Anatomy and Neurobiology at the University of Tennessee Health Science Center as a postdoctoral research associate and was granted Young Investigator Awards from the National Alliance for Research on Schizophrenia and Depression (NARSAD) and the Tourette Syndrome Association to study the roles of intrinsic ion channels and their modulation by neurotrasmitters in regulating the excitability of neostriatal neurons. In 1995, he received an NIH FIRST award and continued this research as an assistant professor in the Department of Psychology at the University of Connecticut. In 1998, Dr. Nisenbaum joined Eli Lilly where his research has focused on the biophysical mechanisms and functional consequences of allosteric regulation of ionotropic and metabotropic glutamate receptors and voltage-gated ion channels. He has led multiple cross-functional discovery efforts for glutamate receptor modulators as novel therapies for chronic pain, migraine, cognitive deficits in schizophrenia and neurodegeneration in Parkinson’s Disease. These efforts have contributed to the advancement of several promising drug candidates to the clinic.

    Gordon Munro

    Senior Scientist, Danish Headache Centre
    Gordon Munro

    Gordon Munro is a senior scientist at the Danish Headache Center in Copenhagen. A transition from academic research in opioids/neuroendocrinology into pain drug discovery started at NeuroSearch in 2001 and continued at Lundbeck, where pain activities focused primarily on developing modulators of ion channels as novel analgesics. A strong emphasis on animal pain models and behavioral pharmacology has contributed to the publication of 70 peer-reviewed articles, numerous patents and the clinical development of 4 pain-related compounds. He is also associated with the Danish biotech Hoba Therapeutics who are currently developing a novel neurotrophic protein for the treatment of neuropathic pain.

    Iain Chessell

    VP & Head, IMED Neuroscience , AstraZeneca
    Iain Chessell

    Dr. Iain Chessell is the Head of the Neuroscience Innovative medicines unit at AstraZeneca, based in Cambridge UK, leading a cross-functional team dedicated to discovery and clinical development of the neuroscience portfolio.Dr. Chessell joined the AstraZeneca (AZ) subsidiary, MedImmune, in November 2008 as vice president, Research, with the intent of initiating neuroscience R&D at MedImmune. After building a portfolio in analgesia and neurodegeneration, in 2010 he was promoted to vice president and head of the Neuroscience Center of Excellence (CoE) and subsequently head of the AstraZeneca neuroscience innovative medicines unit. Dr Chessell also serves on the AstraZeneca IMED leadership team which has responsibility for running the AZ’s discovery and early development organisation. Prior to joining AZ, Dr. Chessell was chief executive officer at NeuroDiscovery where he completed a number of Phase 1 and Phase 2 clinical programs for analgesia. Previously, he was global head of pain R&D for GlaxoSmithKline, where he delivered a portfolio of clinical candidates, and was involved in 19 clinical development projects from Phase 1 to Phase 3. He was also responsible for review of potential in-license opportunities, and was chair of the core disease teams for pain and neurodegeneration, as well as serving as chair of the Neurology management team. Dr. Chessell also managed several high profile academic and industrial collaborations, and is author of more than 95 peer reviewed publications. Dr. Chessell received his bachelor’s degree in pharmacology from University College London, and received his doctoral degree from the Department of Neurochemistry at the Institute of Neurology, London.

    Jean Deregnaucourt

    Scientific Director, Innopain
    Jean Deregnaucourt

    D V M, Thesis Prize Winner, Graduate in Pharmacology (Paris Medical Faculty), Post doctoral fellow at UCLA, was until recently Exec VP Bus Dev at Pasteur Institute after being CEO of the Medicen Paris Region Biocluster. His previous positions were VP Project Management, then VP Chemical and Pharm Dev at Rhone Poulenc Rorer (1990-1998) and later, President of the Pierre Fabre Laboratories R&D (1998-2003). He contributed to the international developments and worldwide registrations of a dozen of products among them two blockbusters, Clexane and Taxotere. Very recently, FDA approved Fetzimab an antidepressor, he patented a few years ago. Since 2016, Jean is now Chief Scientific Director at Innopain.

    Jenny Laird

    Senior Director, Search & Evaluation at Eli Lilly, Eli Lilly And Company
    Jenny Laird

    Jennifer Laird, Ph.D., D.Sc. is Senior Director, Search & Evaluation at Eli Lilly and Company, based at Lilly’s European Headquarters near London. The Search & Evaluation team complements Lilly’s internal R&D efforts by evaluating and in-licensing assets and technologies and by collaborating with external partners to advance molecules through discovery and development. Dr. Laird joined Lilly in 2012; prior to that, she spent 10 years at AstraZeneca as Executive Director heading the Translational Science department in Neuroscience and Project Director leading preclinical and early development projects. Dr. Laird received doctorates from Bristol University and University of Alicante, Spain, serves as an Editorial Board member of Neuropharmacology and European Journal of Pain and holds an honorary appointment as Profe

    Joanne Taylor

    VP, Head of Neuroscience, Prescient Healthcare Group
    Joanne Taylor

    Joseph Stauffer

    Chief Medical Officer, Cara Therapeutics
    Joseph Stauffer

    As well as his position at Cara Therapeutics, Joe is also the Founder of Alta Life Sciences, LLC, a boutique pharmaceutical/investment consulting firm. He is a 2002 founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). In 2011, under the FDA’s Critical Path Initiative, this collaboration became an official public-private partnership between pharma, FDA, NIH, academia and patient advocacy associations. In 2005 he served as an expert member of the FDA/Mayo Clinic Working group on Patient Reported Outcomes and co-authored the supportive paper (Value in Health, Nov/Dec 2007) on validation of self-reported outcome measures.
    In 2007 he was named one of the “100 Most Inspiring People” by PharmaVOICE magazine. In 2011 he was selected as a Board member of the American Academy of Pain Medicine Foundation. In 2014 he was appointed to the Board of Directors of TrialScope, a provider of technology enhanced clinical trial solutions and services.
     

    Kerrie Brady

    Chief Business Officer, Executive VP Strategy, Centrexion Therapeutics Corp.
    Kerrie Brady

    Kerrie Brady is a founder and chief business officer of Centrexion Therapeutics. Kerrie’s career includes 30 years of experience as an international pharmaceutical executive working in both big pharma and biotech companies. Prior to joining Centrexion, Kerrie was the chief operations officer for Vallinex Inc., a company she founded as a spin out from Arcion Therapeutics, Inc., a biotech company developing topical products for the treatment of neuropathic pain. Kerrie was also the co-founder and chief operations officer for Arcion Therapeutics Inc. Previously, she was the founder, president and chief executive officer of Traxion Therapeutics, Inc., a biotech company focused on the development of new drugs to treat intractable pain. Prior to starting on the entrepreneurial path Kerrie’s experience spanned business development (KMG Japan, Entremed, Intracel), business operations (CMC for Biopharmaceutical Research), marketing and regulatory affairs (Rhone Poulenc) Kerrie holds a BPharm from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in biopharmaceuticals from the University of New South Wales. In 2016, Kerrie was named to the PharmaVOICE100 Most Inspiring People for her contributions to the life-sciences industry.

    Lisa Broad

    Senior Research Advisor , Eli Lilly and Company
    Lisa Broad

    Lisa Broad, Ph.D. is a Senior Research Advisor within the Neuroscience division at Eli Lilly and Company, based at Lilly’s European Headquarters near London. Dr. Broad heads up a pre-clinical Neurophysiology group working on Pain/Migraine and Neurodegeneration. Prior to joining Lilly in 2000, Dr. Broad completed post-doctoral studies at the National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA and the University of Cambridge. Dr. Broad received her doctorate from the University of Cambridge in 1997.

    Mark Field

    SVP, Head Global Clinical Development , Grunenthal Gmb H
    Mark Field

    Randall Stevens

    Chief Medical Officer, Centrexion Therapeutics Corp.
    Randall Stevens

    Randall Stevens, M.D. joined Centrexion Therapeutics as the Chief Medical Officer in April 2015. Randall is a board certified internist and rheumatologist with more than 25 years in pharmaceutical medicine. Prior to joining Centrexion, he served as the Corporate Vice President, Head of Inflammation and Immunology Clinical Development of Celgene Corporation. Earlier in his career, Randall spent 11 years at F. Hoffmann La Roche where he was a global leader in inflammation and immunology clinical research. In total, Randall has played an integral role in bringing five drugs to market. Additionally, he is Clinical Professor of Medicine at Robert Wood Johnson School of Medicine and on the faculty since 1987.

    Simon Ruini

    Director, phd pharma design
    Simon Ruini

    Stephen Doberstein

    Senior Vice President, Research and Development and Chief R&D Officer, Nektar Therapeutics
    Stephen Doberstein

    Theo Meert

    Head of Global Government Grant Office, Janssen Pharmaceutical NV, J&J
    Theo Meert

    Prof Theo F. Meert is head of the R&D Global Government Grant office (G3O) of J&J. He is also a professor and scientific advisor/researcher at different universities: Leuven, Antwerp, Brussels, Hasselt and Ghent.
    During his career at J&J that started in 1981, Dr. Meert has been appointed to multiple international global functions. Within his various functions, he guided different multidisciplinary research teams in the field of CNS (Psychiatry - Addiction - Pain -Neurology/ Alzheimer). The activities of these groups covered the complete drug discovery process from early drug candidate selection to POC and further clinical testing. He was a key driver for several advanced projects in the CNS area leading to marketed drugs. Dr. Meert also supports some Full Development products and is involved in the scientific support of novel and marketed products. Dr. Meert has constructed an extensive network within J&J and external scientific and clinical organizations. He has also built an external network of external partnership initiatives and was instrumental in various novel external innovation models.

    Dr. Meert’s scientific expertise is reflected in multiple patents (>15), publications (> 243), congress communications (> 200) and invited lectures (>190). Dr. Meert obtained a Ph.D. in psychopharmacology in Experimental Psychology at the University of Brussels (1986) and a Ph.D. in Medicine/Anesthesiology at the University of Antwerp (1994).
     

    Toni Williamson

    Senior Director Non-Clinical Research, Flexion Therapeutics
    Toni Williamson

    Toni Williamson joined Flexion Therapeutics as Senior Director of Non-Clinical Research in 2015. Prior to joining Flexion, Toni spent 10 years at Amgen, initially managing the Alzheimer’s disease in vivo pharmacology group and leading small molecule drug discovery teams. She then moved into Toxicology, supporting projects from early discovery to clinical development, predominantly in the Neuroscience Therapeutic Area. Prior to joining Amgen, Toni led the Alzheimer’s disease in vivo biochemistry group at Merck, Sharpe and Dohme, and prior to Merck, she was Head of Biological Models at Trophos, a start-up company focused on neurodegenerative diseases. Toni received her bachelor’s degree in Biochemistry & Physiology from the University of Reading, and her PhD from King’s College London. Toni did her post-doctoral research in Dr. Don Cleveland’s laboratory (UCSD).

    Torsten Madsen

    CMO, Aptinyx
    Torsten Madsen

    Dr Torsten Madsen holds and MD and a Ph.D. in neuroscience, both from Copenhagen University. He did clinical training in medicine and psychiatry at Danish University hospitals, and pursued basic research as a postdoc at laboratory for Molecular Psychiatry at Yale. After he joined Lundbeck, he oversaw the development of early and late phase drugs across all phases of development, through to approval. At Aptinyx, he is responsible for clinical development of a portfolio of NMDA receptor modulators.

    William Schmidt

    Vice President, Clinical Development , Viromed
    William Schmidt

    Dr. Schmidt has more than 30 years of experience in pain medicine pharmaceutical development. He is President of NorthStar Consulting, LLC, which specializes in providing advice on preclinical and clinical studies of novel analgesic drugs to pharma and biotech companies worldwide, and simultaneously part-time VP of Clinical Development for ViroMed Co., Ltd. (Seoul, South Korea). In previous assignments, Dr. Schmidt was a key member of teams leading to the development and regulatory approval of Entereg® (alvimopan), a peripherally-acting opioid antagonist, Acelex® (polmacoxib), a dual-acting COX-2 and carbonic anhydrase inhibitor, nalbuphine (Nubain®), naltrexone (ReVia®) and the oxycodone-ibuprofen formulation used in Combunox™. Dr. Schmidt received his Ph.D. in Pharmacology from the University of California, San Francisco.

    Yanina Flossbach

    Associate Medical Director Neuroscience , Novartis Pharmaceuticals
    Yanina Flossbach

    Sponsors and Exhibitors

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Sponsors and Exhibitors


    Lotus Clinical Research

    Sponsors and Exhibitors
    http://www.LotusCR.com


    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.